Tags

Type your tag names separated by a space and hit enter

Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors.
N Engl J Med. 1988 Sep 08; 319(10):605-7.NEJM

Abstract

Over a five-year period, we measured concentrations of gut hormones in plasma samples from 353 patients in whom diagnoses of pancreatic endocrine tumors were subsequently confirmed. A median of 19 months (range, 7 to 120) after the initial diagnosis, 24 of these patients (6.8 percent) had elevated concentrations of other hormones in association with new clinical symptoms. In 13 of these patients (8 with glucagonomas, 3 with tumors secreting vasoactive intestinal polypeptide, and 2 with insulinomas), hypergastrinemia developed along with the clinical features of a gastrinoma; 5 patients died of gastrointestinal perforation or bleeding, apparently caused by this second tumor. We conclude that patients with pancreatic endocrine tumors, regardless of their initial clinical picture, require continued surveillance for new elevations of hormones.

Authors+Show Affiliations

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2842676

Citation

Wynick, D, et al. "Symptomatic Secondary Hormone Syndromes in Patients With Established Malignant Pancreatic Endocrine Tumors." The New England Journal of Medicine, vol. 319, no. 10, 1988, pp. 605-7.
Wynick D, Williams SJ, Bloom SR. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med. 1988;319(10):605-7.
Wynick, D., Williams, S. J., & Bloom, S. R. (1988). Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. The New England Journal of Medicine, 319(10), 605-7.
Wynick D, Williams SJ, Bloom SR. Symptomatic Secondary Hormone Syndromes in Patients With Established Malignant Pancreatic Endocrine Tumors. N Engl J Med. 1988 Sep 8;319(10):605-7. PubMed PMID: 2842676.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. AU - Wynick,D, AU - Williams,S J, AU - Bloom,S R, PY - 1988/9/8/pubmed PY - 1988/9/8/medline PY - 1988/9/8/entrez SP - 605 EP - 7 JF - The New England journal of medicine JO - N Engl J Med VL - 319 IS - 10 N2 - Over a five-year period, we measured concentrations of gut hormones in plasma samples from 353 patients in whom diagnoses of pancreatic endocrine tumors were subsequently confirmed. A median of 19 months (range, 7 to 120) after the initial diagnosis, 24 of these patients (6.8 percent) had elevated concentrations of other hormones in association with new clinical symptoms. In 13 of these patients (8 with glucagonomas, 3 with tumors secreting vasoactive intestinal polypeptide, and 2 with insulinomas), hypergastrinemia developed along with the clinical features of a gastrinoma; 5 patients died of gastrointestinal perforation or bleeding, apparently caused by this second tumor. We conclude that patients with pancreatic endocrine tumors, regardless of their initial clinical picture, require continued surveillance for new elevations of hormones. SN - 0028-4793 UR - https://www.unboundmedicine.com/medline/citation/2842676/Symptomatic_secondary_hormone_syndromes_in_patients_with_established_malignant_pancreatic_endocrine_tumors_ L2 - https://www.nejm.org/doi/10.1056/NEJM198809083191003?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -